Home
Clinical Trials
Comparing Combinations of Tar...

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Last Updated: 2025-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

66 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-05

Study Completion Date

2027-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. To compare investigator-assessed progression-free survival (IA-PFS) between participants with EGFR mutated, MET amplified non-small cell lung cancer (NSCLC) randomized to INC280 (capmatinib) and osimertinib with or without ramucirumab.

SECONDARY OBJECTIVES:

I. To evaluate if the combination of INC280 (capmatinib), osimertinib and ramucirumab or INC280 (capmatinib) and osimertinib during the first cycle of treatment has an acceptable toxicity rate.

II. To evaluate the frequency and severity of toxicities within the arms. III. To compare IA-PFS between the arms, in the subset of participants with centrally-confirmed MET amplification in tissue.

IV. To compare IA-PFS between the arms, in the subset of participants with centrally-confirmed MET amplification based on circulating tumor deoxyribonucleic acid (ctDNA).

V. To compare IA-PFS between the randomized arms in the subsets of participants with and without history of brain metastases.

VI. To compare the objective response rate (ORR) (confirmed and unconfirmed, complete and partial) between the arms among participants with measurable disease at baseline.

VII. To compare overall survival between the arms. VIII. To compare IA-PFS between the randomized arms in the subsets of patients who have received only 1 prior line of therapy and those who have received 2 or more prior lines of therapy.

IX. To evaluate duration of response among responders within each arm.

TRANSLATIONAL MEDICINE OBJECTIVES:

I. To collect, process, and bank cell-free deoxyribonucleic acid (ctDNA) prior to treatment (Cycle 1 Day 1), Cycle 1 Day 15, Cycle 3 Day 1, and first progression for future development of a proposal to evaluate comprehensive next-generation sequencing of circulating tumor deoxyribonucleic acid (ctDNA).

II. To establish a tissue/blood repository from participants with refractory non-small cell lung cancer (NSCLC).

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive capmatinib orally (PO), osimertinib PO, and ramucirumab intravenously (IV) on study. Patients also undergo computed tomography (CT) scan or magnetic resonance imaging (MRI) and collection of blood samples throughout the trial.

ARM B: Patients receive capmatinib PO and osimertinib PO on study. Patients also undergo CT scan or MRI and collection of blood samples throughout the trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Lung Non-Small Cell Carcinoma Stage IV Lung Cancer AJCC v8

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Intervention Type PROCEDURE

Undergo MRI

Osimertinib

Intervention Type DRUG

Given PO

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biospecimen Collection

Undergo collection of blood samples

Intervention Type PROCEDURE

Capmatinib

Given PO

Intervention Type DRUG

Computed Tomography

Undergo CT scan

Intervention Type PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Intervention Type PROCEDURE

Osimertinib

Given PO

Intervention Type DRUG

Ramucirumab

Given IV

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Biological Sample Collection Biospecimen Collected Specimen Collection INC-280 INC280 INCB 28060 INCB028060 INCB28060 CAT CAT Scan Computed Axial Tomography Computerized Axial Tomography Computerized Tomography CT CT Scan tomography Magnetic Resonance Magnetic Resonance Imaging Scan Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance MR MR Imaging MRI MRI Scan NMR Imaging NMRI Nuclear Magnetic Resonance Imaging AZD-9291 AZD9291 Mereletinib Tagrisso Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B Cyramza IMC-1121B LY3009806 Monoclonal Antibody HGS-ETR2

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON ELIGIBILITY CRITERIA as specified in S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
* Participants must have been assigned to S1900G by the Southwest Oncology Group (SWOG) Statistics and Data Management Center (SDMC). Assignment to S1900G is determined by the LUNGMAP protocol
* Participants must have documentation of NSCLC with a sensitizing EGFR mutation and have radiologically or clinically progressed (in the opinion of the treating physician) on osimertinib, alone or in combination with other agent(s), as their most recent line of therapy. Any number of prior lines of therapy is allowed
* Participants must have a MET amplification determined by tissue-based or blood-based (circulating tumor DNA \[ctDNA\]) next generation sequencing (NGS) assay. MET amplifications may have been determined based on tissue submitted for testing by Foundation Medicine Inc (FMI) through the LUNGMAP screening protocol or using test results completed outside of the study. Tissue or blood must be obtained after disease progression on osimertinib (alone or in combination with another agent\[s\]). The testing must be done within a laboratory with Clinical Laboratory Improvement Act (CLIA), International Organization for Standardization (ISO)/Independent Ethics Committee (IEC), College of American Pathologists (CAP), or similar certification

* Note: Participants previously tested for and determined to have MET amplified NSCLC, at the time of progression on osimertinib, outside of LUNGMAP, must also submit tissue for central FMI testing on the LUNGMAP screening protocol, if available
* Participants must have either measurable disease or non-measurable disease documented by CT or MRI. The CT from a combined PET/CT may be used to document only non-measurable disease unless it is of diagnostic quality. Measurable disease must be assessed within 28 days prior to sub-study randomization. Non-measurable disease must be assessed within 42 days prior to sub-study randomization. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form. Participants whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to sub-study randomization to be considered measurable
* Participants must have a CT with contrast or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 42 days prior to sub-study randomization
* Participants with symptomatic CNS metastasis (brain metastases or leptomeningeal disease) must be neurologically stable and have a stable or decreasing corticosteroid requirement for at least 5 days before sub-study randomization
* Participants must have recovered (=\< grade 1) from any side effects of prior therapy, except for alopecia and vitiligo
* Participants must be able to swallow tablets whole
* Absolute neutrophil count \>= 1.5 x 10\^3/uL (within 28 days prior to sub-study randomization)
* Hemoglobin \< 9.0 g/dL (within 28 days prior to sub-study randomization)
* Platelets \>= 100 x 10\^3/uL (within 28 days prior to sub-study randomization)
* Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) unless history of Gilbert's disease (within 28 days prior to sub-study randomization). Participants with history of Gilbert's disease must have total bilirubin =\< 5 x institutional ULN
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x institutional ULN. Participants with history of liver metastasis must have AST =\< 5 x ULN (within 28 days prior to sub-study randomization)
* Participants must have a serum creatinine =\< the IULN OR calculated creatinine clearance \>= 50 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to sub-study randomization
* Participants' most recent Zubrod performance status must be 0-1 and be documented within 28 days prior to sub-study randomization
* Participants must have an electrocardiogram (ECG) performed, with a Fridericia's Correction Formula (QTcF) =\< 470 msec, within 28 days prior to sub-study randomization. It is suggested that a local cardiologist review the QTcF intervals
* Participants must have a completed medical history and physical exam within 28 days prior to sub-study randomization
* Participants must have a urinalysis performed 28 days prior to sub-study randomization. Participant must have a urinary protein =\< 1+ on dipstick or routine urinalysis (UA). Random analysis of urine protein with a normal value is sufficient. If urine dipstick or routine analysis indicated proteinuria \>= 2+, then a 24-hour urine is to be collected and demonstrate \< 2000 mg of protein in 24 hours to allow participation in the study
* Participants must have an International Normalized Ratio (INR) =\< 1.5 seconds above the institutional upper limit of normal (IULN) (unless receiving anticoagulation therapy) documented within 28 days to sub-study randomization. Participants must have a partial thromboplastin time (PTT) =\< 5 seconds above the 'institutional upper limit of normal (IULN) (unless receiving anticoagulation therapy) documented within 28 days prior to sub-study randomization
* Participants with known human immunodeficiency virus (HIV) infection must be on effective anti-retroviral therapy at randomization and have undetectable viral load within 6 months prior to sub-study randomization
* Participants must have asymptomatic serum amylase =\< 2 x ULN and serum lipase =\< ULN obtained within 28 days prior to sub-study randomization. Asymptomatic is defined as having no signs and/ or symptoms suggesting pancreatitis or pancreatic injury (e.g. elevated P. amylase, abnormal imaging findings of pancreas, etc.)
* Participants must have adequate cardiac function. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better
* Participants must agree to have blood specimens submitted for circulating tumor DNA (ctDNA)
* Participants must also be offered participation in specimen banking. With participant consent, specimens must be collected and submitted via the SWOG Specimen Tracking System
* Note: As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
* Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
* Participants with impaired decision-making capacity must not have a neurological or psychological condition that precludes their safe participation in the study (e.g., tracking pill consumption and reporting adverse events to the investigator). For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations

Exclusion Criteria

* Participants must not have received an anti-VEGF or VEGFR inhibitor or MET inhibitor
* Participants must not have received any anti-cancer drug (investigational or standard of care drug, except osimertinib) within 21 days prior to sub-study randomization

* Note: osimertinib may continue up to the day prior to study treatment initiation
* Participants must not have received any radiation therapy within 14 days prior to sub-study randomization
* Participants must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment while receiving treatment on this study
* Participants must not have had a major surgery within 14 days prior to sub-study randomization. Participants must have fully recovered from the effects of prior surgery in the opinion of the treating investigator
* Participants must not have received a live attenuated vaccination within 28 days prior to sub-study randomization. All COVID-19 vaccines that have received Food and Drug Administration (FDA) approval or FDA emergency use authorization are acceptable
* Participants must not have received strong inducers of CYP3A4 (including herbal supplements such as St. John's Wort); CYP3A4 inhibitors; CYP1A2 substrates; P-gp and BCRP substrates; sensitive substrates of MATE1 and MATE2K; or drugs that are known to prolong QT interval within 7 days prior to sub-study registration and must not be planning to use any of these throughout protocol treatment
* Participants must not have uncontrolled blood pressure and hypertension within 28 days prior to sub-study randomization
* Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen
* Participants must not be pregnant or breastfeeding (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sarah B Goldberg

Role: PRINCIPAL_INVESTIGATOR

SWOG Cancer Research Network

Role: primary

501-686-8274

Site Public Contact

Role: primary

[email protected]

702-384-0013

Site Public Contact

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

Role: primary

909-558-4050

Site Public Contact

Role: primary

310-423-8965

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

877-642-4691

Site Public Contact

Role: primary

[email protected]

Site Public Contact

Role: primary

916-734-3089

Role: primary

Role: primary

954-265-4325

Site Public Contact

Role: primary

[email protected]

800-679-0775

Site Public Contact

Role: primary

[email protected]

Site Public Contact

Role: primary

888-946-7447

Role: primary

808-532-0315

Site Public Contact

Role: primary

808-545-8548

[email protected]

312-226-2371

Role: primary

815-285-7800

Site Public Contact

Role: primary

[email protected]

630-275-1270

Site Public Contact

Role: primary

[email protected]

800-446-5532

Site Public Contact

Role: primary

[email protected]

217-876-4762

Role: primary

312-695-1102

Site Public Contact

Role: primary

312-695-1102

Site Public Contact

Role: primary

708-799-9995

Site Public Contact

Role: primary

708-202-8387

Site Public Contact

Role: primary

[email protected]

309-243-3605

Role: primary

[email protected]

309-243-3605

Site Public Contact

Role: primary

[email protected]

309-243-3605

Site Public Contact

Role: primary

[email protected]

309-243-3605

Site Public Contact

Role: primary

815-227-2633

Site Public Contact

Role: primary

217-545-7929

Role: primary

515-241-3305

Site Public Contact

Role: primary

515-241-3305

Site Public Contact

Role: primary

515-241-6727

Site Public Contact

Role: primary

515-241-3305

Site Public Contact

Role: primary

[email protected]

515-358-6613

Site Public Contact

Role: primary

515-241-3305

Site Public Contact

Role: primary

515-241-3305

Site Public Contact

Role: primary

[email protected]

913-588-3671

Role: primary

785-295-8000

Site Public Contact

Role: primary

[email protected]

913-588-3671

Site Public Contact

Role: primary

859-257-3379

Site Public Contact

Role: primary

800-987-3005

Site Public Contact

Role: primary

[email protected]

240-632-4285

601-815-6700

Site Public Contact

Role: primary

[email protected]

901-226-1366

Site Public Contact

Role: primary

[email protected]

901-226-1366

Site Public Contact

Role: primary

[email protected]

901-226-1366

Site Public Contact

Role: primary

[email protected]

573-334-2230

Site Public Contact

Role: primary

314-996-5569

Site Public Contact

Role: primary

816-404-4375

Role: primary

314-996-5569

Site Public Contact

Role: primary

[email protected]

314-525-6042

Site Public Contact

Role: primary

314-996-5569

Site Public Contact

Role: primary

314-251-7066

Site Public Contact

Role: primary

314-996-5569

Role: primary

603-224-2556

[email protected]

937-528-2900

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

412-389-5208

Site Public Contact

Role: primary

[email protected]

412-389-5208

Site Public Contact

Role: primary

[email protected]

Role: primary

717-721-4840

Site Public Contact

Role: primary

[email protected]

412-389-5208

Site Public Contact

Role: primary

[email protected]

Site Public Contact

Role: primary

877-441-7957

Role: primary

814-534-4724

Site Public Contact

Role: primary

[email protected]

717-741-8303

Site Public Contact

Role: primary

[email protected]

570-374-8555

Role: primary

724-230-3030

Site Public Contact

Role: primary

[email protected]

412-389-5208

Site Public Contact

Role: primary

Role: primary

Site Public Contact

Role: primary

[email protected]

Site Public Contact

Role: primary

877-441-7957

Role: primary

802-225-5400

Site Public Contact

Role: primary

[email protected]

434-243-6303

Site Public Contact

Role: primary

[email protected]

240-632-4285

Site Public Contact

Role: primary

[email protected]

240-632-4285

877-405-6866

Site Public Contact

Role: primary

[email protected]

414-302-2304

Site Public Contact

Role: primary

[email protected]

414-302-2304

Site Public Contact

Role: primary

[email protected]

800-782-8581

Site Public Contact

Role: primary

715-422-7718

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2022-09254

Identifier Type: REGISTRY

Identifier Source: secondary_id

S1900G

Identifier Type: OTHER

Identifier Source: secondary_id

S1900G

Identifier Type: OTHER

Identifier Source: secondary_id

U10CA180888

Identifier Type: NIH

Identifier Source: secondary_id

View Link

S1900G

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

NCT06908772 NOT_YET_RECRUITING PHASE2/PHASE3

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

NCT01887886 COMPLETED PHASE3

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

NCT05801029 ACTIVE_NOT_RECRUITING PHASE2

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

NCT02335944 TERMINATED PHASE1/PHASE2

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

NCT01610336 COMPLETED PHASE2

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

NCT04780568 RECRUITING PHASE1

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

NCT05401110 RECRUITING PHASE1

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

NCT07028489 RECRUITING

First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer

NCT03804580 ACTIVE_NOT_RECRUITING PHASE2

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

NCT06538038 RECRUITING

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

NCT03434418 COMPLETED PHASE2

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

NCT02468661 TERMINATED PHASE1

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.

NCT00773383 TERMINATED PHASE2

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

NCT01221077 COMPLETED PHASE2

Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

NCT04677595 COMPLETED PHASE2

Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC

NCT03684967 WITHDRAWN PHASE2

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

NCT06010329 RECRUITING PHASE2

Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

NCT04545710 ACTIVE_NOT_RECRUITING PHASE2

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

NCT07230691 RECRUITING

Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation

NCT03693339 UNKNOWN PHASE2

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

NCT02759835 COMPLETED PHASE2

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

NCT03240393 WITHDRAWN PHASE2

Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)

NCT00577707 COMPLETED PHASE2

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

NCT04460729 WITHDRAWN PHASE2

Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy

NCT00801385 UNKNOWN PHASE2

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Study Results

Basic Information

Brief Summary

Related Clinical Trials

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Detailed Description

Conditions

Study Design

Study Groups

Arm A (capmatinib, osimertinib, ramucirumab)

Biospecimen Collection

Capmatinib

Computed Tomography

Magnetic Resonance Imaging

Osimertinib

Ramucirumab

Arm B (capmatinib, osimertinib)

Biospecimen Collection

Capmatinib

Computed Tomography

Magnetic Resonance Imaging

Osimertinib

Interventions

Biospecimen Collection

Capmatinib

Computed Tomography

Magnetic Resonance Imaging

Osimertinib

Ramucirumab

Other Intervention Names

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

National Cancer Institute (NCI)

SWOG Cancer Research Network

Responsible Party

Principal Investigators

Sarah B Goldberg

Locations

Katmai Oncology Group

Kingman Regional Medical Center

Cancer Center at Saint Joseph's

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

University of Arkansas for Medical Sciences

Kaiser Permanente-Anaheim

Mission Hope Medical Oncology - Arroyo Grande

PCR Oncology

Sutter Auburn Faith Hospital

Kaiser Permanente-Baldwin Park

Kaiser Permanente-Bellflower

Alta Bates Summit Medical Center-Herrick Campus

Tower Cancer Research Foundation

Mercy Cancer Center - Carmichael

Mercy San Juan Medical Center

Mercy Cancer Center - Elk Grove

Kaiser Permanente-Fontana

Palo Alto Medical Foundation-Fremont

Kaiser Permanente-Fresno

Kaiser Permanente South Bay

Kaiser Permanente-Irvine

UC San Diego Moores Cancer Center

Loma Linda University Medical Center

Kaiser Permanente Los Angeles Medical Center

Kaiser Permanente West Los Angeles

Cedars Sinai Medical Center

Memorial Medical Center

Kaiser Permanente-Oakland

Kaiser Permanente-Ontario

Palo Alto Medical Foundation Health Care

Kaiser Permanente - Panorama City

Kaiser Permanente-Riverside

Mercy Cancer Center - Rocklin

Kaiser Permanente-Roseville

Sutter Roseville Medical Center